Literature DB >> 33627696

Association of coagulation dysfunction with cardiac injury among hospitalized patients with COVID-19.

Liang Chen1, Wei Hu2, Xiaoxiao Guo2, Ping Zhao3, Jia Tang2, Yuwei Gu2, Ninghao Huang3, Chao Wang2, An Cui2, Dian Zhang2, Linjie Hu3, Yi Feng4, Shengshou Hu1, Mingquan Chen5, Firat Duru6,7, Chenglong Xiong8,9.   

Abstract

Cardiac injury is a common complication of the coronavirus disease 2019 (COVID-19), and is associated with adverse clinical outcomes. In this study, we aimed to reveal the association of cardiac injury with coagulation dysfunction. We enrolled 181 consecutive patients who were hospitalized with COVID-19, and studied the clinical characteristics and outcome of these patients. Cardiac biomarkers high-sensitivity troponin I (hs-cTnI), myohemoglobin and creatine kinase-myocardial band (CK-MB) were assessed in all patients. The clinical outcomes were defined as hospital discharge or death. The median age of the study cohort was 55 (IQR, 46-65) years, and 102 (56.4%) were males. Forty-two of the 181 patients (23.2%) had cardiac injury. Old age, high leukocyte count, and high levels of aspartate transaminase (AST), D-dimer and serum ferritin were significantly associated with cardiac injury. Multivariate regression analysis revealed old age and elevated D-dimer levels as being strong risk predictors of in-hospital mortality. Interleukin 6 (IL6) levels were comparable in patients with or without cardiac injury. Serial observations of coagulation parameters demonstrated highly synchronous alterations of D-dimer along with progression to cardiac injury. Cardiac injury is a common complication of COVID-19 and is an independent risk factor for in-hospital mortality. Old age, high leukocyte count, and high levels of AST, D-dimer and serum ferritin are significantly associated with cardiac injury, whereas IL6 are not. Therefore, the pathogenesis of cardiac injury in COVID-19 may be primarily due to coagulation dysfunction along with microvascular injury.

Entities:  

Year:  2021        PMID: 33627696     DOI: 10.1038/s41598-021-83822-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  5 in total

1.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

2.  Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.

Authors:  Henny H Billett; Morayma Reyes-Gil; James Szymanski; Kenji Ikemura; Lindsay R Stahl; Yungtai Lo; Shafia Rahman; Jesus D Gonzalez-Lugo; Margarita Kushnir; Mohammad Barouqa; Ladan Golestaneh; Eran Bellin
Journal:  Thromb Haemost       Date:  2020-11-13       Impact factor: 5.249

3.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

4.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

Authors:  Tao Chen; Di Wu; Huilong Chen; Weiming Yan; Danlei Yang; Guang Chen; Ke Ma; Dong Xu; Haijing Yu; Hongwu Wang; Tao Wang; Wei Guo; Jia Chen; Chen Ding; Xiaoping Zhang; Jiaquan Huang; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  BMJ       Date:  2020-03-26

5.  Elevated α-hydroxybutyrate dehydrogenase as an independent prognostic factor for mortality in hospitalized patients with COVID-19.

Authors:  Zeming Liu; Jinpeng Li; Man Li; Sichao Chen; Rongfen Gao; Guang Zeng; Danyang Chen; Shipei Wang; Qianqian Li; Di Hu; Wen Zeng; Liang Guo; Xiaohui Wu
Journal:  ESC Heart Fail       Date:  2020-12-17
  5 in total
  4 in total

Review 1.  Myocardial injuries among patients with COVID-19: a systematic review.

Authors:  Alaa Hasan Alali; Mustafa Samir Smaisem; Ahmed Mohammed Alsheikh; Aljohara Abdullah Alshareef; Fatema Samir Smaisem; Batool Wael Alnahar; Amal Khalil Hassouneh; Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Infez Med       Date:  2021-09-10

Review 2.  Cardiovascular System during SARS-CoV-2 Infection.

Authors:  Maciej Koźlik; Adrianna Błahuszewska; Maciej Kaźmierski
Journal:  Int J Environ Res Public Health       Date:  2022-01-21       Impact factor: 3.390

3.  Acute Myocardial Injury Assessed by High-Sensitive Cardiac Troponin Predicting Severe Outcomes and Death in Hospitalized Patients with COVID-19 Infection.

Authors:  Falmata Laouan Brem; Miri Chaymae; Hammam Rasras; Manal Merbouh; Mohammed-Amine Bouazzaoui; Houssam Bkiyar; Naima Abda; Bazid Zakaria; Nabila Ismaili; Brahim Housni; Noha El Ouafi
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

4.  The prognostic value of myocardial injury in COVID-19 patients and associated characteristics.

Authors:  Jian He; Bicheng Zhang; Quan Zhou; Wenjing Yang; Jing Xu; Tingting Liu; Haijun Zhang; Zhiyong Wu; Dong Li; Qing Zhou; Jie Yan; Cuizhen Zhang; Haiyan Qian; Minjie Lu; Xiaoyang Zhou
Journal:  Immun Inflamm Dis       Date:  2021-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.